Annals of Family Medicine
NOVEMBER 20, 2024
Methods: Following the Joanna Briggs Institute guidelines and PRISMA-ScR standards, a comprehensive search was conducted across multiple databases, including PUBMED, Embase, PsycINFO, CINAHL, Cochrane Library, CBM, and CNKI, covering the literature from January 2004 to December 2023.
Family Medicine Initiative
APRIL 9, 2024
Yes, one year after stopping the medication, patients regain ½ – ⅔ of their previous weight loss: What are other clinical benefits? 13 Here is some evidence: From 2004-2020, 8,718 GLP-1 analogs-associated tumors were reported to the FDA. Tirzepatide (15 mg) showed slightly more noticeable effects than Semaglutide (2.4
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Clinical Problem Solvers
MAY 11, 2023
Rafa presents a nephrology clinical unknown to Drs. She was the Nephrology Fellowship Training Program Director from 2004-2010 and is now the Associate Program Director. Ashita Tolwani and Mustafa Muhammad. Case discussants: Dr. Ashita Tolwani, Professor of Medicine at the University of Alabama at Birmingham (UAB).
The Clinical Problem Solvers
FEBRUARY 24, 2021
In contrast, scholarship and clinical care which acknowledges within-group differences and shifts from a deficit-based to an asset-based view of marginalized groups can help us better serve our minoritized patients. Interpretations of ‘appropriate’ minority inclusion in clinical research. 2004 Feb 15;116(4):249-52.
The Clinical Problem Solvers
MAY 9, 2021
The answer to this question may not be easily answered and may not always be found in the clinical setting. The use of race is based on a false/biological concept of race AND many studies show that this can harm patients ( i.e. clinical resources are withheld based on results of algorithm).
FDA Law Blog
JANUARY 12, 2025
Background on Accelerated Approval The key concept, an ingenuity of FDA itself that has been around since the beginning of accelerated approval, is to allow earlier access to a promising therapy for a serious condition with an unmet medical need based on an endpoint that is reasonably likely to predict clinical benefit.
FDA Law Blog
AUGUST 4, 2023
Because anabolic steroids are also abused to enhance athletic performance and increase muscle strength, Congress has enacted three laws regulating anabolic steroids: the Anabolic Steroid Control Acts of 1990 and 2004, and the Designer Anabolic Steroid Control Act of 2014 (“DASCA”). at 50,040 codified at 21 C.F.R.
Expert insights. Personalized for you.
130 
Let's personalize your content